K idney disease-related anemia is highly prevalent among patients with end-stage renal disease and is associated with significant and debilitating morbidity, as well as increased risk for mortality. 1 In patients with end-stage renal disease who undergo hemodialysis, kidney disease-related anemia is typically treated with both erythropoiesis-stimulating agents (ESAs) and intravenous (IV) iron. 2, 3 These treatments have been the standard of care for decades.
A significant proportion of patients with kidney disease-related anemia undergoing hemodialysis do not respond as anticipated: either they cannot achieve the targeted hemoglobin value or they require persistently high ESA doses to achieve targets. The mechanisms for reduced ESA responsiveness are not entirely delineated, but evidence indicates mediating roles of inflammation, iron deficiency (absolute or functional), inadequate vitamin D, 4 and underlying illnesses or infections. 5 Past studies have shown that greater ESA hyporesponsiveness is associated with poor survival, 6, 7 and other studies have indicated that high ESA doses may contribute to poor patient outcomes. 2, 3, [8] [9] [10] [11] Although prior studies of hyporesponsiveness did not conform to a single consensus definition (no such definition exists), all based ESA hyporesponsiveness on ESA doses and/or hemoglobin levels, each evaluated with respect to population distributions.
In 2011, there were marked changes in ESA dosing practices among US hemodialysis patients. During that year, there were changes to both US dialysis remuneration policy for injected drugs for dialysis patients and ESA product labeling, resulting in marked ESA dose reductions for the treatment of kidney disease-related anemia. [12] [13] [14] In parallel, the distribution of hemoglobin levels shifted downward in the US dialysis population. Because ESA hyporesponsiveness is defined with respect to ESA dose and hemoglobin levels, it is unclear whether findings from these prior studies pertain in contemporary nephrology anemia treatment practice: even recently published studies of ESA hyporesponsiveness have considered data from prior to 2011. 15 We undertook the present study to identify a definition of ESA hyporesponsiveness that is relevant in today's ESA dosing environment and to use that definition to examine the prevalence of ESA hyporesponsiveness and the association of ESA hyporesponsiveness with clinical (hemoglobin concentrations, mortality and missed hemodialysis treatment rates) and health care utilization (cumulative ESA and iron use) outcomes.
METHODS

Data and Patient Cohort
Data for our retrospective study were abstracted from the electronic health record of a large dialysis organization. The large dialysis organization data set contains information about patient demographics, disease history, comorbid conditions, dialysisspecific information for each treatment session, laboratory results such as hemoglobin levels, and IV anemia medications administered at dialysis sessions (ESAs and iron).
Patients eligible for the analysis were 18 years or older, were not Veterans Affairs beneficiaries (contractual stipulation), received in-center hemodialysis at the large dialysis organization, and had a dialysis vintage of 6 months or longer to allow for stabilization of ESA dose following dialysis therapy initiation. In a majority of patients, ESA and iron dosing followed one of the large dialysis organization's clinical protocols: for each, 3 protocols of varying intensity are in place; physicians may choose among these or treat off-protocol. In rare cases in which patients were treated with agents other than epoetin alfa (eg, darbepoetin alfa) or other dosing frequencies were used, ESA dose units were converted based on manufacturer recommendations. 16 For descriptive analyses, we considered the point prevalent cohort of eligible patients at the start of each of 8 consecutive calendar quarters from quarter 1 (Q1), 2012, through Q4, 2013 (Fig 1) . Within each cohort, we calculated the point prevalence of ESA hyporesponsiveness using each of 5 candidate definitions: (1) 2 most recent hemoglobin measurements, separated by 141 days, both ,10 g/dL; (2) 2 most recent hemoglobin measurements, separated by 141 days, both ,9.5 g/dL; (3) ESA dose . 7,700 U/treatment (this corresponds to the 80th percentile for dose among the cohort and is approximately equivalent to a dose of 23,100 U/wk); (4) meets criteria for definitions 1 and 3; and (5) meets criteria for definitions 2 and 3. Point prevalence was defined as the number of patients affected on the first date of the quarter divided by the number of patients in total.
For associative analyses, we considered the point prevalent cohort of eligible patients at the start of Q1 in 2012. Exposure status was assigned as ESA hyporesponsiveness or non-ESA hyporesponsiveness based on whether the patient met definition 4 of ESA hyporesponsiveness at any point during Q1 in 2012 (Fig 1) . Patients were followed forward in historical time until the earliest of death, loss to follow-up (transfer of care, transplantation, or withdrawal from dialysis therapy), or end of study (December 31, 2013) .
Baseline patient characteristics for the associative analysis (eg, demographics and comorbid conditions) were determined as of the start of Q1 2012; described as means, standard deviations, medians, interquartile ranges, counts, and proportions; and compared using t tests, Wilcoxon rank sum tests, and c 2 tests, as dictated by data type. Continuous patient baseline variables and mean medication dosages were determined using data available up to 90 days prior to January 1, 2012 (study initiation). In rare instances for which patient data were not available in the prior quarter, January 2012 data were used to capture baseline variables. During followup, ESA use was analyzed on a monthly basis as mean dose administered per dialysis session, considering all attended dialysis treatments (ie, opportunities to receive ESA) so as to account for treatments with zero dose. However, extra dialysis treatments (including isolated ultrafiltration sessions) were not considered because ESA is not administered during these. Hemoglobin level was calculated on a monthly basis during follow-up as the mean of all measurements made during the month (typically 2). On a monthly basis during follow-up, IV iron use was considered as the cumulative dose administered during the month. Deaths were determined on a quarterly basis during follow-up and expressed as rates: number of deaths during the quarter divided by cumulative time at risk during the quarter. Missed hemodialysis treatments were assessed because they are: (1) important clinical events in their own right, (2) important economic levers for dialysis providers, and (3) surrogate indicators for acute health events that are not well captured in standard data sources such as claims (ie, due to delays) and electronic health records (ie, due to limited sensitivity). Missed hemodialysis treatments were considered on a quarterly basis during follow-up and expressed as rates.
Statistical Comparisons
Associations of ESA hyporesponsiveness status with outcomes of interest were estimated using generalized estimating equation (GEE) models to account for longitudinally correlated response data. All GEE models considered the main effect of exposure status (ESA hyporesponsiveness), time, and a 1-way ESA hyporesponsiveness-by-time cross-product term, the latter to account for differences over time in the association between exposure groups. The quasi-likelihood under the independence model criterion approach was used to select a working correlation structure. Demographic, comorbid condition, and clinical covariates that were imbalanced between exposure groups and had observed associations with the outcomes of interest on bivariable testing were considered for inclusion in the models. Priority was given to variables with the most clinical significance. In rare cases in which including a particular variable resulted in the failure of the model to converge, we recharacterized the variable to reduce the possibility of data separation. If this remedy failed, the variable was not used in the model. Thus, the list of covariates adjusted for differed slightly for each outcome analyzed.
Associations of ESA hyporesponsiveness status with hemoglobin levels and the use of ESA and IV iron were estimated by GEE models using an identity link, autoregressive correlation structure, and Gaussian distribution, and associations of ESA hyporesponsiveness status with mortality and missed hemodialysis treatment rates were estimated by GEE models using a log link, exchangeable correlation structure, and Poisson (mortality) or negative binomial (missed treatments) distribution, respectively. For ESA, the response variable was divided by 100 and its rescaled value was used in the model to improve numeric stability. Estimates were back converted and displayed on the native scale.
All statistical analyses were conducted using SAS, version 9.3 (SAS Institute Inc).
Compliance and Patient Protections
We conducted our observational study retrospectively using deidentified patient data; therefore, according to 45 CFR part 46 from the US Department of Health and Human Services, this study was exempt from institutional review board or ethics committee approval. We adhered to the Declaration of Helsinki and informed consent was not required.
RESULTS
Candidate Definitions of ESA Hyporesponsiveness
The point prevalence (schema in Fig 1) of ESA hyporesponsiveness according to each of the 5 candidate definitions is presented in Table 1 . Between Q1 2012 and Q4 2013, prevalence ranged from 29.6% to 22.4% using definition 1, 14.6% to 10.8% using definition 2, 25.4% to 22.2% using definition 3, 12.5% to 9.0% using definition 4, and 7.7% to 5.6% using definition 5. Definition 4 was selected because it most closely aligned with prior definitions conceptually and in terms of anticipated prevalence of ESA hyporesponsiveness (w10%).
15,17
Patient Demographics
For longitudinal associative analyses (schema in Fig 1) , we characterized patients as having or not having ESA hyporesponsiveness based on whether they met definition 4 at any time point during Q1 2012. Baseline characteristics of patients with and without ESA hyporesponsiveness are provided in Table 2 . As anticipated, median per-treatment ESA use was higher among patients with ESA hyporesponsiveness than those without (7,000 vs 1,742 U/treatment), and mean monthly hemoglobin concentration was lower (9.9 vs 11.2 g/dL). Beyond these implicit differences Other statistically significant differences were observed, but in general, the magnitude of these remaining differences was small.
Anemia and Anemia Medication Use
Using intention-to-treat principles, we followed patients' indices of anemia management forward in historical time based on their initial ESA hyporesponsiveness or non-hyporesponsiveness characterization. Figure 2 displays mean adjusted and unadjusted ESA use, hemoglobin concentrations, and IV iron use during the 24 months of follow-up for the ESA hyporesponsive and nonhyporesponsive groups. During month 1, mean adjusted per-treatment ESA use was 9,586 units for patients with ESA hyporesponsiveness and 2,904 units for patients without ESA hyporesponsiveness (Fig 2A) . During the course of study, mean ESA use declined among the ESA hyporesponsive group (to 7,951 U/treatment by the last month of follow-up) but remained essentially stable among the nonhyporesponsive group (3,009 U/treatment in the last month of follow-up). The resulting between-group difference thus narrowed during follow-up (from w3-fold to w2-fold) and remained clinically and statistically significant at all times (P , 0.001 for each month of follow-up). During month 1, adjusted mean hemoglobin concentrations were 9.8 g/dL for patients with ESA hyporesponsiveness and 10.8 g/dL for patients without (Fig 2B) . During the course of study, hemoglobin levels increased among patients in the ESA hyporesponsive group (to 10.3 g/dL in the last month of study) and remained essentially constant among the non-hyporesponsive group (10.8 g/dL in the last month of study). Betweengroup differences in hemoglobin levels were highly statistically significant in every month (P , 0.001). The ESA hyporesponsive group had greater IV iron use than the non-hyporesponsive group in every month, but the magnitude of difference was modest (Fig 2C) . Patient baseline continuous variables were determined using results obtained up to 90 days prior to the beginning of the identification window (January 1, 2012), and patients were followed forward until censoring or study end. In rare instances, when there were no claims data available prior to January 1, 2012, January 2012 data were used to capture baseline variables.
Clinical Outcomes
Again using intention-to-treat principles, we followed patients' clinical outcomes forward in time based on their initial ESA hyporesponsiveness characterization. Figure 3 displays adjusted and unadjusted incidence rate ratios (IRRs) for mortality by quarter over the study. During Q1, the unadjusted IRR for mortality among patients with ESA hyporesponsiveness was not significantly different from that of patients without ESA hyporesponsiveness (Fig 3A) . Thereafter, mortality risk increased among patients with ESA hyporesponsiveness and remained significantly greater than that of their nonhyporesponsive counterparts for the duration of follow up. Unadjusted IRRs peaked at 2.19 (95% confidence interval [CI], 2.01-2.39) during Q2 and gradually declined, reaching a plateau at w1.5 during the last 3 quarters of follow-up (Q8: unadjusted IRR, 1.45; 95% CI, 1.29-1.64). Adjusted IRRs for mortality were identical in trend and similar in values to unadjusted IRRs during the study period (Fig 3B) . Table 3 reports the adjusted rate of missed hemodialysis treatments during follow-up. The missed treatment rate was significantly higher among patients with ESA hyporesponsiveness at all points during follow up. During Q1, patients with ESA hyporesponsiveness had an average of 2.64 more missed hemodialysis treatments per quarter (P , 0.001). The magnitude of association attenuated modestly during the course of follow-up, reaching a plateau at 1.47 incremental missed hemodialysis treatment per month over Q5 through Q8. The reported associations between ESA hyporesponsiveness status, mortality, and missed hemodialysis treatments were not materially different when 985 patients with identified non-kidney disease-related causes of anemia (sickle cell anemia, monoclonal gammopathy, and myelodysplastic syndrome) were excluded from analysis.
DISCUSSION
ESA hyporesponsiveness is a physiologic condition that is identified clinically by a combination of somewhat arbitrary cutoffs in terms of ESA dose and hemoglobin concentration. Although first-line treatments for kidney disease-related anemia, namely ESA and IV iron, have been the standard of care for decades, 18,19 normative practices with respect to ESA dosing and hemoglobin level targeting have changed in recent years in response to financial and regulatory events. 12, 13 It therefore could be anticipated that the clinical expression of ESA hyporesponsiveness might change. In this study, we sought to identify an operational definition of ESA hyporesponsiveness that is relevant in contemporary clinical practice. Criteria for defining ESA hyporesponsiveness have varied across studies of hemodialysis patients, and the definitions used have taken into consideration both ESA dose and hemoglobin concentration or hematocrit, 20, 21 including the duration of elevated ESA dosing requirement, 15, 22 or have used the erythropoietin resistance index (weekly weight-adjusted ESA dose [U/kg/wk] divided by hemoglobin concentration [g/dL]). 23 In hemodialysis patients, the prevalence of ESA hyporesponsiveness has been estimated at 5% to 15%. 15, 17, 20 In our analysis, we determined that among candidate definitions, the combination of ESA dose . 7,700 U/treatment (corresponding to a weekly dose . 23,100 units) along with hemoglobin level , 10 g/dL on each of 2 successive bimonthly measurements met with prior expectations with regard to the prevalence of ESA hyporesponsiveness: approximately 9% to 12% of hemodialysis patients receiving ESA therapy at any time.
Older studies using era-appropriate definitions have demonstrated that ESA hyporesponsiveness is associated with death, kidney transplant failure, vitamin D deficiency, and hemoglobin level variability. 11, 24, 25 It is notable that the presence of ESA hyporesponsiveness, as defined using our operational definition, was likewise associated with enhanced mortality risk compared to its absence. It is also noteworthy that the mortality association was highly potent (1.5-to 2.5-fold) and the association persisted for at least 2 years after ESA hyporesponsiveness status was ascribed.
It is unclear whether ESA hyporesponsiveness is a causal determinant of mortality (perhaps due to toxic effects of resultantly high doses of ESA) or whether the excess in mortality relates to the conditions that render patients ESA hyporesponsive, or other differences between patients with ESA hyporesponsiveness and patients without. This study cannot make that distinction. We note that among measurable differences versus patients without ESA hyporesponsiveness, patients with ESA hyporesponsiveness had some characteristics that might favor positive A B Figure 3 . Quarterly mortality incidence rate ratios (IRRs) during follow-up for patients with versus without erythropoiesis-stimulating agent hyporesponsiveness at baseline. Shown are the (A) unadjusted and (B) adjusted IRRs with 95% confidence intervals (CIs). Mortality rates, estimated using general estimating equation Poisson models with exchangeable correlation structure, were adjusted for differences at baseline in age, sex, cause of end-stage renal disease, dialysis vintage, vascular access, cancer, cerebrovascular disease, heart failure, chronic obstructive pulmonary disease, coronary artery disease, gastrointestinal bleeding, human immunodeficiency virus/AIDS, peripheral vascular disease, intravenous (IV) antibiotic use, dry weight, serum ferritin level, saturated transferrin, parathyroid hormone level, albumin level, IV vitamin D use, and Charlson Comorbidity Index score. The interaction between exposure and quarter was significant, P , 0.001. In determining all IRRs, ESA non-hyporesponsiveness rates served as the referent. Missed treatments per quarter. Adjusted rate estimates using generalized estimating equations negative binomial model with exchangeable correlation structure were adjusted for differences at baseline in age, sex, cause of end-stage renal disease, vintage, vascular access, cancer, cerebrovascular disease, heart failure, chronic obstructive pulmonary disease, coronary artery disease, gastrointestinal bleeding, human immunodeficiency virus/AIDS, peripheral vascular disease, intravenous antibiotic use, dry weight, serum ferritin level, saturated transferrin, parathyroid hormone level, albumin level, intravenous vitamin D use, and Charlson Comorbidity Index score. The interaction between exposure and quarter is significant, P , 0.001.
prognosis (younger and more likely to be African American) and other characteristics that might favor a negative prognosis (greater catheter use and greater antibiotic use). We controlled for such differences analytically to the degree possible. However, because the precise mechanisms underlying ESA hyporesponsiveness are not fully elaborated and due to data limitations, we could not control for all factors that rendered patients hyporesponsive and therefore cannot assess causality. Clinical trials are needed to assess whether and why ESA hyporesponsiveness causes death. In the meantime, it can be said that ESA hyporesponsiveness is a potent prognostic marker for risk of death.
We also found that ESA hyporesponsiveness was potently and persistently associated with a greater rate of missed hemodialysis treatments. As such, ESA hyporesponsiveness is highly relevant to dialysis providers economically because foregone revenue from missed treatments is among their largest variable (opportunity) costs. 26 Moreover, because missed hemodialysis treatments frequently result from hospitalizations, it is likely that ESA hyporesponsiveness is associated with greater rates of hospital admissions. If true, this would have broader economic implications for payors and taxpayers. However, limitations in the source data prevented empirical confirmation of the ESA hyporesponsiveness-hospitalization link (ie, claims data needed to identify hospitalizations become available only after a several-year lag and are not yet available for the period being studied), and further study is needed in this area.
As implied by the operational definition, baseline ESA use was greater (w3-fold) and hemoglobin levels were lower (w1.0 g/dL) among patients with ESA hyporesponsiveness than patients without ESA hyporesponsiveness. As anticipated, these differences attenuated during the course of follow-up. This attenuation was likely derived from at least 2 factors. First, patients with ESA hyporesponsiveness due to acute illness recover from these illnesses and restitute ESA responsiveness. Second, among patients with ESA hyporesponsiveness, there is a selective attrition of the sickest patients. In general, these will be the patients with the greatest ESA use and lowest hemoglobin levels. As a result, over time, mean ESA use will decrease and mean hemoglobin level will increase. Collectively, these factors are referred to as regression to the mean and can be anticipated in any instance in which eligibility is contingent on disease severity. Considering this, it is remarkable that the separation in ESA use and hemoglobin levels persisted and remained potent (about 2-fold and 0.6 g/dL, respectively) for at least 2 years after ESA hyporesponsiveness status was ascribed.
As noted previously, the reasons that patients had ESA hyporesponsiveness are not known, both because the spectrum of antecedent causes is not fully elucidated and because many of the causes that are known are not reliably captured in clinical databases. One obvious potential cause is iron deficiency. These data suggest that absolute iron deficiency was not a primary determinant of ESA hyporesponsiveness in our population. 3, 27 Baseline ferritin levels were higher among patients with ESA hyporesponsiveness than those without, and patients with ESA hyporesponsiveness also received greater amounts of IV iron throughout follow-up. We cannot assess the impact of functional iron deficiency on ESA hyporesponsiveness because of the interdependent nature of pathways mediating ESA responsiveness and iron metabolism. 28 However, it is worth noting that, in our study, transferrin saturation percentage values were lower among patients with ESA hyporesponsiveness than among patients without ESA hyporesponsiveness, which may suggest a link.
Some study limitations have already been noted; however, one limitation bears particular mention. Although we attempted to formulate informed candidate definitions of ESA hyporesponsiveness based on our experience and literature precedent, it is possible that an alternative definition may be optimal (ie, more tightly associated with patient outcomes). As such, the associations we observed may be conservative estimates of true relationships.
This study represents the first analysis of ESA hyporesponsiveness since the 2011 changes in the US ESA labels and reimbursement policy and the concomitant changes in ESA dosing practices. In the context of these changes, we identified a new operational definition of ESA hyporesponsiveness that is conceptually aligned with the underlying construct, meets with expectations regarding its historical prevalence, and is relevant in contemporary practice. Using this new definition, we observed potent and persistent associations of ESA hyporesponsiveness with lower hemoglobin concentrations and greater rates of ESA use, missed hemodialysis treatments, and mortality, as had been reported previously using older definitions of ESA hyporesponsiveness. At a minimum, ESA hyporesponsiveness, as defined here, can be considered to be a prognostic marker with important clinical and economic implications. Further studies are needed to assess causality and, as warranted, therapeutic intervention.
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